U.S. Transportation Stock News

Lineage (NasdaqGS:LINE) was added to both the Russell 2500 Index and the Russell 2500 Value Benchmark on 27 June 2026. This change can influence how index funds and institutional investors approach the stock. See our latest analysis for Lineage. At a share price of $44.00, Lineage has a 90 day share price return of 34.76% and a year to date share price return of 24.22%, while its 1 year total shareholder return of 9.02% suggests more modest gains for longer term holders. If this index...

The Sherwin-Williams Company recently selected Square as its payment solutions partner for the Sherwin-Williams Digital Alliance Program, giving PRO+ customers in the US and Canada access to integrated invoicing, multiple payment options, and cash flow tools through Square’s single platform. This collaboration deepens Sherwin-Williams’ ties with professional contractors by embedding digital payments and customer management directly into day-to-day project workflows, potentially strengthening...

Arrowhead Pharmaceuticals stock reacts to index reshuffle and EU drug approval Arrowhead Pharmaceuticals (ARWR) has been in focus after multiple Russell index changes on June 27 and a recent European Commission marketing authorization for its triglyceride lowering drug REDEMPLO for adults with familial chylomicronemia syndrome. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals shares have been strong recently, with a 1-day share price return of 4.41%, a 30-day...

Earlier this week, KE Holdings Inc. approved the grant of 7,025,385 restricted share units to 649 employees under its 2020 Share Incentive Plan, to be settled in Class A ordinary shares listed in Hong Kong. This combination of broad-based equity awards and recent HK$20,000,000 in share repurchases highlights management’s emphasis on long-term alignment with shareholders. Next, we’ll examine how the large restricted share unit grant shapes KE Holdings’ investment narrative and longer-term...

Valaris (VAL) recently reported quarterly revenue of $465.4 million, which declined 25% year on year but came in 5.6% above analyst expectations, along with beats on EPS and EBITDA estimates. See our latest analysis for Valaris. Valaris shares trade at $75.35, with the stock up 44.49% based on the year to date share price return and a 65.82% total shareholder return over one year. Recent 30 and 90 day share price returns indicate fading momentum after the earnings beat and index reshuffling...

With the May jobs report expected to show only 80,000 new positions, and some forecasts pointing to as few as 20,000, the labor market is flashing a warning light for stocks tied closely to hiring and payrolls. Unemployment holding around 4.3% to 4.4% and the highest planned job cuts for May since 2020, including many linked to AI, put human capital services companies under pressure. This article reviews 3 stocks that appear more exposed to these headwinds and aims to help you decide whether...

In recent days, Peloton Interactive reported a mixed quarter, including a revenue beat alongside weaker full-year guidance and the announced departure of its CFO, while reiterating efforts to cut costs and refine its product portfolio. At the same time, bullish commentators have highlighted Peloton’s subscription-focused turnaround plan, pointing to improving operating discipline, AI-enabled features, and upcoming product launches as potential levers to stabilize engagement and reshape its...

Viridian Therapeutics recently reported that the U.S. Food and Drug Administration approved Lumvoa (veligrotug-vvze), an intravenous IGF-1R antagonist, for the treatment of thyroid eye disease, covering both active and chronic forms based on the THRIVE and THRIVE-2 phase 3 trials. This approval not only gives Viridian its first commercial product but also introduces the first TED therapy with labeling that includes data for both disease stages and statistically significant effects on...

Institutional capital is flowing into private credit again, with North American direct lending funds attracting at least $16b in Q2 and signaling that big investors are still keen on alternative lenders even as smaller clients pull back. That kind of funding backdrop can reshape how credit is provided, how risk is priced, and which stocks stand to benefit or face pressure. This article explains what that shift in funding might mean for your portfolio and highlights 3 stocks exposed to this...

In June 2026, BILL Holdings, Inc. appointed Jonathan Leaf as Chief Revenue Officer, placing him in charge of global sales, marketing, embedded partnerships, and customer experience, reporting directly to CEO and Founder René Lacerte. The move consolidates BILL’s go-to-market and customer-facing functions under a single executive with extensive experience scaling revenue organizations at large technology companies, while outgoing Chief Customer Officer Sarah Acton supports the transition in...

Glaukos (GKOS) is back in focus after completing patient enrollment for its Phase 2 GLK-321 trial targeting Demodex blepharitis, a move that coincides with rising expectations around its Epioxa glaucoma franchise. See our latest analysis for Glaukos. The GLK-321 update has arrived alongside a sharp pick up in momentum, with Glaukos posting a 1-day share price return of 7.83% and a 30-day share price return of 18.67%. Its 1-year total shareholder return of 46.21% and 3-year total shareholder...

Index reshuffle and product expansion put DoubleVerify in focus DoubleVerify Holdings (DV) has been reshuffled across the Russell index family, moving out of several Russell 1000 and Midcap benchmarks and into multiple Russell 2000 variants, while also extending its DV Authentic AdVantage solution to Meta and TikTok. These parallel developments highlight how the stock now sits in a different index peer group just as the company broadens distribution of a key media effectiveness product across...

Index changes put Distribution Solutions Group back on investors’ radar Distribution Solutions Group (DSGR) was recently removed from several Russell 2000 Defensive indexes. This is a technical shift that can influence passive fund flows, liquidity, and how some investors view the stock. For you as a shareholder or potential buyer, this type of index exclusion is less about company operations and more about understanding who might be trading the stock and why. It often reflects index...

UFP Technologies, Inc. was recently removed from the Russell 2000 Dynamic Index, a change that can alter how index-linked investors treat the stock. This index exit highlights how index membership itself can influence trading volumes and ownership mix for a specialized medical components manufacturer like UFP Technologies. We will now examine how UFP Technologies’ removal from the Russell 2000 Dynamic Index may influence its existing investment narrative and risk profile. The future of work...

In recent months, NextEra Energy has emphasized its role in powering AI-driven data centers and reaffirmed guidance for high-single-digit adjusted EPS growth and dividend increases of about 10% annually through 2026 and 6% through 2028. This combination of growing data-center electricity needs and a reinforced dividend-growth outlook has pushed the company further into focus for income-oriented investors seeking exposure to long-term power demand. Next, we’ll examine how NextEra’s push...

Becton Dickinson recently saw the FDA revoke the Emergency Use Authorization for its BD Veritor rapid SARS-CoV-2 test at the company’s request, while the firm was also added to the Russell Midcap Index and Russell Midcap Value Index and removed from the Russell Top 200 Index and Russell Top 200 Value Index. Earlier in June, Vizient awarded BD’s CentroVena One Insertion System an Innovative Technology contract, signaling hospital decision-makers see its all-in-one central line solution as...

In late June 2026, Unity Software Inc. (NYSE: U) was removed as a constituent from several major Russell growth indexes, including the Russell 1000 Growth and Russell Midcap Growth benchmarks. This broad index exclusion reshapes how Unity screens for growth-style funds, potentially altering its institutional investor mix without directly changing its underlying business trajectory. Next, we’ll examine how Unity’s removal from multiple Russell growth benchmarks may interact with its...

In late June 2026, Novanta Inc. filed a shelf registration to offer up to US$337.61 million, or 2,142,857 common shares, giving the company pre-approved flexibility to issue equity as needed over time. This potential equity raise matters because it could change Novanta’s capital structure and future funding mix, influencing how investors weigh its growth plans against possible dilution. Against this backdrop of potential equity issuance to bolster financial flexibility, we’ll now examine how...

Nvidia’s delay to its Kyber NVL144 AI rack system has opened an unexpected window where competitors with solid balance sheets and credible AI hardware ambitions could attract fresh attention. The screener here focuses on large semiconductor companies with strong financial health and growth potential that are exposed to this news, rather than on Nvidia itself. For investors weighing how this delay might reshape high end AI infrastructure, the key question is which stocks could benefit from...

John Wiley & Sons, Inc. recently declared a quarterly cash dividend of US$0.3575 per share, lifting its annual payout to US$1.43 and marking the company’s 33rd consecutive yearly increase, alongside completing a buyback of 1,268,383 shares under its June 2025 repurchase program. This combination of a higher dividend and ongoing share repurchases underscores Wiley’s emphasis on consistent cash returns to investors as it advances its research and learning businesses. We’ll now examine how...

Recently, Charles River Laboratories International received upgrades from Morgan Stanley and CLSA, with both firms citing stronger biopharma funding trends and a more supportive regulatory backdrop in China as reasons for a more positive long-term view. This shift in analyst sentiment stands in contrast to recent concerns around softer organic revenue and weaker returns on new investments, highlighting how funding momentum and regulatory tailwinds can reshape expectations for the company’s...

In late June 2026, Exelixis, Inc. was removed from three Russell 1000 Defensive-style indexes just as it reported final subgroup overall survival results from its pivotal STELLAR-303 trial of investigational kinase inhibitor zanzalintinib in metastatic colorectal cancer and advanced its related FDA review. The mixed picture of a statistically significant overall survival benefit in the full trial population, a non-significant trend in a key subgroup, and an analyst downgrade on pipeline...

Index removal puts DiamondRock Hospitality in focus DiamondRock Hospitality (DRH) has been removed from the Russell 2000 Dynamic Index, a change that can influence institutional ownership patterns and prompt investors to reassess how the stock fits into their portfolios. See our latest analysis for DiamondRock Hospitality. Recent price action around the index change has come after a period where DiamondRock Hospitality’s 90 day share price return of 28.78% and 1 year total shareholder return...

Recently, Murphy USA outlined plans to compound growth by leveraging fuel price volatility, opening roughly 50 new stores each year, and continuing disciplined share repurchases to support earnings. This combination of fuel economics, measured network expansion, and ongoing capital returns highlights how management is attempting to steadily enhance the company’s earnings power over time. Next, we’ll examine how Murphy USA’s emphasis on store expansion and disciplined buybacks could reshape...